Amarillo Biosciences Partner, CytoPharm, to Conduct 144 Patient Phase 2 Hepatitis C Trial in Taiwan

Published: Feb 19, 2008

AMARILLO, TX--(Marketwire - February 19, 2008) - Amarillo Biosciences, Inc.(OTCBB: AMAR) today announced that the U.S. Food and Drug Administration has allowed the Investigational New Drug (IND) application submitted by the Company to test its low dose oral interferon in a Phase 2 hepatitis C clinical trial to go into effect. Accordingly, CytoPharm Inc., the Company's partner in Taiwan, will fund and conduct a clinical trial of 144 chronic hepatitis C patients in Taiwan. The patients will receive one of two different dosages of oral human interferon alpha or placebo

Back to news